$ODYY
Odyssey Group of Companies Stock $odyy

$odyy Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000168316823008887 Filed on December 15, 2023

Income Statement

Concept	2023 Q4	2022 Q4
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development	$25.84K	$354.2K
YoY Change	-92.7%	9.83%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$25.84K	$354.2K
YoY Change	-92.7%	9.83%
Operating Profit	-$847.2K	-$2.078M
YoY Change	-59.22%	45.36%
Interest Expense	$190.9K	$71.30K
YoY Change	167.68%	-67.12%
% of Operating Profit
Other Income/Expense, Net	$65.00	-$474.00
YoY Change	-113.71%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings	-$538.0K	-$2.150M
YoY Change	-74.97%	30.57%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.01	-$0.03
Diluted Earnings Per Share	-$0.01	-$0.03
COMMON SHARES
Basic Shares Outstanding	81.73M shares	71.99M shares
Diluted Shares Outstanding	81.02M shares	80.89M shares

Balance Sheet

Concept	2023 Q4	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$197.9K	$50.50K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$563.1K	$817.2K
YoY Change	-31.09%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$48.96K	$50.54K
YoY Change	-3.13%
TOTAL ASSETS
Total Short-Term Assets	$563.1K	$817.2K
Total Long-Term Assets	$48.96K	$50.54K
Total Assets	$612.0K	$867.7K
YoY Change	-29.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.851M	$2.374M
YoY Change	-22.0%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.830M	$6.252M
YoY Change	9.26%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.830M	$6.252M
Total Long-Term Liabilities
Total Liabilities
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings	-$60.64M	-$56.33M
YoY Change	7.65%
Common Stock	$81.73K	$72.00K
YoY Change	13.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$6.218M	-$5.384M
YoY Change
Total Liabilities & Shareholders Equity	$612.0K	$867.7K
YoY Change	-29.47%

Cashflow Statement

Concept	2023 Q4	2022 Q4
OPERATING ACTIVITIES
Net Income	-$538.0K	-$2.150M
YoY Change	-74.97%	30.57%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$59.91K	-$284.7K
YoY Change	-78.96%	-75.57%
INVESTING ACTIVITIES
Capital Expenditures		$8.038K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	-$8.038K
YoY Change	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$220.9K	$270.7K
YoY Change	-18.39%	-74.93%
NET CHANGE
Cash From Operating Activities	-$59.91K	-$284.7K
Cash From Investing Activities	$0.00	-$8.038K
Cash From Financing Activities	$220.9K	$270.7K
Net Change In Cash	$161.0K	-$22.04K
YoY Change	-830.73%	-74.21%
FREE CASH FLOW
Cash From Operating Activities	-$59.91K	-$284.7K
Capital Expenditures		$8.038K
Free Cash Flow		-$292.7K
YoY Change		-74.88%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	dei	Amendment Flag AmendmentFlag	false
CY2023Q4	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--07-31
CY2023Q4	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2023Q4	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q4	dei	Entity Central Index Key EntityCentralIndexKey	0001626644
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	ODYY	Warrants Exercised In Connection With Debt Financing WarrantsExercisedInConnectionWithDebtFinancing		usd
CY2023Q4	ODYY	Return Of Shares ReturnOfShares		usd
CY2022Q4	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue		usd
CY2023Q4	dei	Document Type DocumentType	10-Q
CY2023Q4	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q4	dei	Document Period End Date DocumentPeriodEndDate	2023-10-31
CY2023Q4	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q4	dei	Entity File Number EntityFileNumber	000-56196
CY2023Q4	dei	Entity Registrant Name EntityRegistrantName	Odyssey Health, Inc.
CY2023Q4	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023Q4	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-1022125
CY2023Q4	dei	Entity Address Address Line1 EntityAddressAddressLine1	2300 West Sahara Avenue
CY2023Q4	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 800 - #4012
CY2023Q4	dei	Entity Address City Or Town EntityAddressCityOrTown	Las Vegas
CY2023Q4	dei	Entity Address State Or Province EntityAddressStateOrProvince	NV
CY2023Q4	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	89102
CY2023Q4	dei	City Area Code CityAreaCode	(702)
CY2023Q4	dei	Local Phone Number LocalPhoneNumber	780-6559
CY2023Q4	dei	Security12b Title Security12bTitle	Common Stock ($0.001 par value)
CY2023Q4	dei	Trading Symbol TradingSymbol	ODYY
CY2023Q4	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q4	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q4	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q4	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q4	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q4	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	83124061	shares
CY2023Q4	us-gaap	Cash Cash	197882	usd
CY2023Q3	us-gaap	Cash Cash	36865	usd
CY2023Q4	ODYY	Research And Development Rebate Due From Australian Government ResearchAndDevelopmentRebateDueFromAustralianGovernment	291036	usd
CY2023Q3	ODYY	Research And Development Rebate Due From Australian Government ResearchAndDevelopmentRebateDueFromAustralianGovernment	276566	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	74160	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	92457	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	563078	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	405888	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	6320	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5376	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	48961	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	49905	usd
CY2023Q4	us-gaap	Assets Assets	612039	usd
CY2023Q3	us-gaap	Assets Assets	455793	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1851443	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1797656	usd
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1338614	usd
CY2023Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1402348	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	164904	usd
CY2023Q3	us-gaap	Interest Payable Current InterestPayableCurrent	142032	usd
CY2023Q4	us-gaap	Assets Sold Under Agreements To Repurchase Repurchase Liability AssetsSoldUnderAgreementsToRepurchaseRepurchaseLiability	1125026	usd
CY2023Q3	us-gaap	Assets Sold Under Agreements To Repurchase Repurchase Liability AssetsSoldUnderAgreementsToRepurchaseRepurchaseLiability	1125026	usd
CY2023Q4	ODYY	Notes Payable Related Parties Classified Current1 NotesPayableRelatedPartiesClassifiedCurrent1	100000	usd
CY2023Q3	ODYY	Notes Payable Related Parties Classified Current1 NotesPayableRelatedPartiesClassifiedCurrent1	125000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	177126	usd
CY2023Q3	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	280340	usd
CY2023Q4	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	2250325	usd
CY2023Q3	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	2019660	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6830312	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	6611722	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	81734061	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	81734061	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	79067879	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	79067879	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	81734	usd
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	79068	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	54335403	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	53862378	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-60635410	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-60097375	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-6218273	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-6155929	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	612039	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	455793	usd
CY2023Q4	us-gaap	Research And Development Expense Software Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost	23001	usd
CY2022Q4	us-gaap	Research And Development Expense Software Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost	354215	usd
CY2023Q4	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	322798	usd
CY2022Q4	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	779890	usd
CY2023Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	501440	usd
CY2022Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	943699	usd
CY2023Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-847239	usd
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-2077804	usd
CY2023Q4	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	500000	usd
CY2022Q4	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	usd
CY2023Q4	us-gaap	Interest Expense InterestExpense	190861	usd
CY2022Q4	us-gaap	Interest Expense InterestExpense	71302	usd
CY2023Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	65	usd
CY2022Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-474	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-538035	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-2149580	usd
CY2023Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2023Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2022Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2023Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	81022472	shares
CY2022Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	80891387	shares
CY2023Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	81022472	shares
CY2022Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	80891387	shares
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-6155929	usd
CY2023Q4	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	322728	usd
CY2023Q4	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	78695	usd
CY2023Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	45820	usd
CY2023Q4	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	28448	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-538035	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-6218273	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-4643617	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1168690	usd
CY2022Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	240710	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-2149580	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-5383797	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-538035	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-2149580	usd
CY2023Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	944	usd
CY2022Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	754	usd
CY2023Q4	us-gaap	Share Based Compensation ShareBasedCompensation	322728	usd
CY2022Q4	us-gaap	Share Based Compensation ShareBasedCompensation	1168690	usd
CY2023Q4	ODYY	Financing Costs Paid Via Issuance Of Common Stock FinancingCostsPaidViaIssuanceOfCommonStock	1750	usd
CY2022Q4	ODYY	Financing Costs Paid Via Issuance Of Common Stock FinancingCostsPaidViaIssuanceOfCommonStock	0	usd
CY2023Q4	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	131662	usd
CY2022Q4	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	68054	usd
CY2023Q4	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-18297	usd
CY2022Q4	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	472	usd
CY2023Q4	ODYY	Increase In Research And Development Rebate Due IncreaseInResearchAndDevelopmentRebateDue	14470	usd
CY2022Q4	ODYY	Increase In Research And Development Rebate Due IncreaseInResearchAndDevelopmentRebateDue	312325	usd
CY2023Q4	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	53787	usd
CY2022Q4	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	824084	usd
CY2023Q4	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	-63734	usd
CY2022Q4	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	113275	usd
CY2023Q4	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	27164	usd
CY2022Q4	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	2813	usd
CY2023Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-59907	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-284707	usd
CY2023Q4	ODYY	Purchase Of Intellectual Property PurchaseOfIntellectualProperty	-0	usd
CY2022Q4	ODYY	Purchase Of Intellectual Property PurchaseOfIntellectualProperty	8038	usd
CY2023Q4	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8038	usd
CY2023Q4	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	350000	usd
CY2022Q4	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	30000	usd
CY2023Q4	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	174896	usd
CY2022Q4	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	-0	usd
CY2023Q4	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	45820	usd
CY2022Q4	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	240710	usd
CY2023Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	220924	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	270710	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	161017	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-22035	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36865	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72534	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	197882	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	50499	usd
CY2023Q4	ODYY	Increase In Principal Of Notes Payable IncreaseInPrincipalOfNotesPayable	0	usd
CY2022Q4	ODYY	Increase In Principal Of Notes Payable IncreaseInPrincipalOfNotesPayable	115000	usd
CY2023Q4	ODYY	Shares Returned To Treasury SharesReturnedToTreasury	100	usd
CY2022Q4	ODYY	Shares Returned To Treasury SharesReturnedToTreasury	8800	usd
CY2023Q4	ODYY	Shares Issued For Exercised Warrants SharesIssuedForExercisedWarrants	1610	usd
CY2022Q4	ODYY	Shares Issued For Exercised Warrants SharesIssuedForExercisedWarrants	0	usd
CY2023Q4	ODYY	Debt Principal Interest And Fees Converted To Common Stock DebtPrincipalInterestAndFeesConvertedToCommonStock	76945	usd
CY2022Q4	ODYY	Debt Principal Interest And Fees Converted To Common Stock DebtPrincipalInterestAndFeesConvertedToCommonStock	0	usd
CY2023Q4	ODYY	Warrants Issued In Connection With Debt Financing WarrantsIssuedInConnectionWithDebtFinancing	28448	usd
CY2022Q4	ODYY	Warrants Issued In Connection With Debt Financing WarrantsIssuedInConnectionWithDebtFinancing	0	usd
CY2023Q4	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_803_eus-gaap--NatureOfOperations_zazRttE8GTG9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 1. <span id="xdx_825_zjl4zo06Nx18">Basis of Presentation and Nature of Operations</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Basis of Presentation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial information of Odyssey Health, Inc. and our wholly-owned subsidiary Odyssey Group International Australia, Pty Ltd, (collectively, the “Company”) is unaudited and has been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). All intercompany balances and transactions have been eliminated. However, such information reflects all adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the consolidated financial position, results of operations and cash flows for the interim periods. The consolidated financial information as of July 31, 2023 is derived from our 2023 Annual Report on Form 10-K. The consolidated financial statements included herein should be read in conjunction with the consolidated financial statements and the notes thereto included in our 2023 Annual Report on Form 10-K filed with the SEC on October 30, 2023. The consolidated results of operations for the interim periods presented are not necessarily indicative of the results to be expected for the full year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Significant Accounting Policies</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our significant accounting policies have not changed during the three months ended October 31, 2023 from those disclosed in our Annual Report on Form 10-K for the year ended July 31, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>OTCQB</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 4, 2023, we uplisted to the OTCQB Market.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Nature of Operations</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our corporate mission is to create or acquire distinct assets, intellectual property, and technologies with an emphasis on acquisition targets that have clinical utility and will generate positive cash flow. Our business model is to develop or acquire medical related products, engage third parties to manufacture such products and then distribute the products through various distribution channels, including third parties. We have three different life saving technologies; the CardioMap® heart monitoring and screening device, the Save a Life choking rescue device and a unique neurosteroid drug compound intended to treat concussions and rare brain disorders. Currently no research and development activities are being incurred on the CardioMap® or the Save a Life devices.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 4, 2023, we entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Oragenics, Inc. (“Oragenics” the “Purchaser”). Pursuant to the Purchase Agreement, we have agreed to sell and assign certain assets and certain liabilities related to a segment of our business focused on developing medical products that treat brain related illnesses and diseases (the “Purchased Assets”) to Oragenics in exchange for (i) $<span id="xdx_903_eus-gaap--CashEquivalentsAtCarryingValue_iI_c20231004__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zHO9lUTiNXMl" title="Cash">1,000,000</span> in cash and <span id="xdx_905_eus-gaap--ConversionOfStockSharesConverted1_c20231003__20231004__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zfHW8wDXJ54j" title="Conversion of shares">8,000,000</span> shares of convertible Series F Preferred Stock. $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_c20231003__20231004__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_ztBGpxASI7Pg" title="Proceeds from conversion of shares">500,000</span> has been received, with $<span id="xdx_905_eus-gaap--ProceedsFromSaleOfOtherAssets1_c20231003__20231004__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zyCKS5925Pbk" title="Proceeds from sale of asset">500,000</span> due the earlier of, stockholder approval of the sale of the asset or 90 days from the signing. The closing is expected to be at the end of the fourth calendar quarter of 2023, subject to the satisfaction of customary closing conditions. See Note 4.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to acquire other technologies and assets and plan to be a trans-disciplinary product development company involved in the discovery, development and commercialization of products and technologies that may be applied over various medical markets. We plan to license, improve and/or develop our products and identify and select distribution channels. We intend to establish agreements with distributors to get products to market quickly as well as to undertake and engage in our own direct marketing efforts. We will determine the most effective method of distribution for each unique product that we include in our portfolio. We will engage third-party research and development firms who specialize in the creation of our products to assist us in the development of our own products and we will apply for trademarks and patents once we have developed proprietary products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are not currently selling or marketing any products, as our products are in development and Food and Drug Administration (“FDA”) clearance or approval to market our products will be required to sell in the United States. In addition, it would require additional European union or country specific clearance or approvals to sell internationally.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Going Concern</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We did not recognize any revenues for the year ended July 31, 2023, or the three months ended October 31, 2023, and we had an accumulated deficit of $<span id="xdx_909_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20231031_zte50o2nJ1xf" title="Accumulated deficit">60,635,410</span> as of October 31, 2023. For the foreseeable future, we expect to experience continuing operating losses and negative cash flows from operations. Cash available at October 31, 2023, of $<span id="xdx_902_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20231031_zkeAhPno9Fd6" title="Cash">197,882</span> will not provide enough working capital to meet our current operating expenses through the second quarter of fiscal 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The operating deficit and cash balance at October 31, 2023 indicate substantial doubt about our ability to continue as a going concern. Our continued existence depends on the success of our efforts to raise additional capital necessary to meet our obligations as they come due and to obtain sufficient capital to execute our business plan. We may obtain capital primarily through issuances of debt or equity or entering into collaborative arrangements with corporate partners. There can be no assurance that we will be successful in completing additional financing or collaboration transactions or, if financing is available, that it can be obtained on commercially reasonable terms. If we are not able to obtain the additional financing on a timely basis, we may be required to scale down or perhaps even cease operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The issuance of additional equity securities could result in a significant dilution in the equity interests of our current stockholders. Obtaining commercial loans, assuming those loans would be available, would increase our liabilities and future cash commitments. Our consolidated financial statements do not include adjustments that might result from the outcome of this uncertainty.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are continually adjusting our business plan to reflect our current liquidity expectations. Due to the unknown and volatile nature of the stock price and trading volume of our common stock, it is difficult to predict the timing and amount of availability pursuant to our equity line of credit with Lincoln Park Capital Fund, LLC (“LPC”). Due to the limitations in the equity line of credit, we will need to do one or more of the following during fiscal 2024; secure additional debt financing, secure additional equity financing, secure a strategic partner, reduce our operating expenditures, or seek bankruptcy protection. Given our recurring losses, negative cash flow, and accumulated deficit, there is substantial doubt about our ability to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-60635410	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	197882	usd
CY2023Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	944	usd
CY2022Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	754	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	2764	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	3685	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3685	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	3685	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	3685	usd
CY2023Q4	ODYY	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	31457	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	48961	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	2527451	usd
CY2023Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	2425000	usd
CY2023Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	2527451	usd
CY2023Q3	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	2425000	usd
CY2023Q4	us-gaap	Notes Payable NotesPayable	2527451	usd
CY2023Q3	us-gaap	Notes Payable NotesPayable	2425000	usd
CY2023Q4	ODYY	Unamortized Debt Discount And Closing Costs UnamortizedDebtDiscountAndClosingCosts	177126	usd
CY2023Q3	ODYY	Unamortized Debt Discount And Closing Costs UnamortizedDebtDiscountAndClosingCosts	280340	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	2350325	usd
CY2023Q3	us-gaap	Notes Payable Current NotesPayableCurrent	2144660	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	693073	usd
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P0Y3M21D
CY2023Q4	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	47640283	shares
CY2022Q4	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	26944955	shares
CY2023Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25843	usd
CY2023Q4	ODYY	Research And Development Rebate ResearchAndDevelopmentRebate	12534	usd
CY2023Q4	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	1210187	usd
CY2023Q3	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	1193602	usd

Files In Submission

Name	View Source	Status
0001683168-23-008887-index-headers.html	Edgar Link	pending
0001683168-23-008887-index.html	Edgar Link	pending
0001683168-23-008887.txt	Edgar Link	pending
0001683168-23-008887-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
odyssey_10q-ex3101.htm	Edgar Link	pending
odyssey_10q-ex3102.htm	Edgar Link	pending
odyssey_10q-ex3201.htm	Edgar Link	pending
odyssey_10q-ex3202.htm	Edgar Link	pending
odyssey_i10q-103123.htm	Edgar Link	pending
odyy-20231031.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
odyy-20231031_cal.xml	Edgar Link	unprocessable
odyy-20231031_def.xml	Edgar Link	unprocessable
odyy-20231031_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
odyy-20231031_pre.xml	Edgar Link	unprocessable
odyssey_i10q-103123_htm.xml	Edgar Link	completed
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ODYY
Odyssey Group of Companies Stock $odyy

2023 Q4 Form 10-Q Financial Statement

#000168316823008887 Filed on December 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ODYY Odyssey Group of Companies Stock $odyy

2023 Q4 Form 10-Q Financial Statement

#000168316823008887 Filed on December 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ODYY
Odyssey Group of Companies Stock $odyy